Expression profiling reveals hepsin overexpression in prostate cancer - PubMed (original) (raw)
. 2001 Aug 1;61(15):5692-6.
Affiliations
- PMID: 11479199
Expression profiling reveals hepsin overexpression in prostate cancer
J A Magee et al. Cancer Res. 2001.
Abstract
Prostate cancer is the most commonly diagnosed noncutaneous cancer in men. Despite this fact, many of the genetic changes that coincide with prostate cancer progression remain enigmatic. We have addressed this problem by characterizing the expression profiles of several benign and malignant human prostate samples, and we have identified several genes that are differentially expressed between benign and malignant glands. One gene that was overexpressed encodes the serine protease hepsin. We used an independent sample set to confirm that hepsin is overexpressed in prostate tumors, and in situ hybridization demonstrates that hepsin is specifically overexpressed in the carcinoma cells themselves. These facts, together with the molecular properties of hepsin, make it an ideal target for prostate cancer therapy.
Similar articles
- Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA, Stamey TA. Chen Z, et al. J Urol. 2003 Apr;169(4):1316-9. doi: 10.1097/01.ju.0000050648.40164.0d. J Urol. 2003. PMID: 12629351 - Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Luo J, et al. Cancer Res. 2001 Jun 15;61(12):4683-8. Cancer Res. 2001. PMID: 11406537 - Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Stephan C, et al. J Urol. 2004 Jan;171(1):187-91. doi: 10.1097/01.ju.0000101622.74236.94. J Urol. 2004. PMID: 14665873 - [Gene expression profiling in prostatic cancer].
Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Ikinger U, Kretzler M, Hollstein M, Gröne HJ. Ernst T, et al. Verh Dtsch Ges Pathol. 2002;86:165-75. Verh Dtsch Ges Pathol. 2002. PMID: 12647366 Review. German. - Genes differentially expressed in prostate cancer.
Eder IE, Bektic J, Haag P, Bartsch G, Klocker H. Eder IE, et al. BJU Int. 2004 May;93(8):1151-5. doi: 10.1111/j.1464-410X.2004.04869.x. BJU Int. 2004. PMID: 15142130 Review.
Cited by
- Molecular signature of cancer at gene level or pathway level? Case studies of colorectal cancer and prostate cancer microarray data.
Chen J, Wang Y, Shen B, Zhang D. Chen J, et al. Comput Math Methods Med. 2013;2013:909525. doi: 10.1155/2013/909525. Epub 2013 Jan 16. Comput Math Methods Med. 2013. PMID: 23401724 Free PMC article. - Regulators of gene expression as biomarkers for prostate cancer.
Willard SS, Koochekpour S. Willard SS, et al. Am J Cancer Res. 2012;2(6):620-57. Epub 2012 Nov 20. Am J Cancer Res. 2012. PMID: 23226612 Free PMC article. - Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Liu B, et al. J Mol Med (Berl). 2007 Oct;85(10):1113-23. doi: 10.1007/s00109-007-0208-z. Epub 2007 Jun 7. J Mol Med (Berl). 2007. PMID: 17554518 - Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors.
Daves MH, Hilsenbeck SG, Lau CC, Man TK. Daves MH, et al. BMC Med Genomics. 2011 Jul 7;4:56. doi: 10.1186/1755-8794-4-56. BMC Med Genomics. 2011. PMID: 21736749 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical